These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
809 related articles for article (PubMed ID: 28497198)
1. Diagnostic performance of Afshar-Oromieh A; Holland-Letz T; Giesel FL; Kratochwil C; Mier W; Haufe S; Debus N; Eder M; Eisenhut M; Schäfer M; Neels O; Hohenfellner M; Kopka K; Kauczor HU; Debus J; Haberkorn U Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1258-1268. PubMed ID: 28497198 [TBL] [Abstract][Full Text] [Related]
2. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132 [TBL] [Abstract][Full Text] [Related]
3. Performance of [ Afshar-Oromieh A; da Cunha ML; Wagner J; Haberkorn U; Debus N; Weber W; Eiber M; Holland-Letz T; Rauscher I Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2925-2934. PubMed ID: 33543325 [TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
5. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121 [TBL] [Abstract][Full Text] [Related]
6. Akdemir EN; Tuncel M; Akyol F; Bilen CY; Baydar DE; Karabulut E; Ozen H; Caglar M World J Urol; 2019 May; 37(5):813-821. PubMed ID: 30151600 [TBL] [Abstract][Full Text] [Related]
15. Clinical Factors That Influence Repeat Thin P; Hotta M; Gafita A; Grogan T; Czernin J; Calais J; Sonni I J Nucl Med; 2024 Oct; 65(10):1571-1576. PubMed ID: 39168522 [TBL] [Abstract][Full Text] [Related]
16. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731 [TBL] [Abstract][Full Text] [Related]
17. Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747 [TBL] [Abstract][Full Text] [Related]
18. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Afshar-Oromieh A; Debus N; Uhrig M; Hope TA; Evans MJ; Holland-Letz T; Giesel FL; Kopka K; Hadaschik B; Kratochwil C; Haberkorn U Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2045-2054. PubMed ID: 29980832 [TBL] [Abstract][Full Text] [Related]
19. Combined Early and Late [ Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521 [TBL] [Abstract][Full Text] [Related]
20. A Multicenter Prospective Clinical Trial of McCarthy M; Francis R; Tang C; Watts J; Campbell A Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]